Dandelion Health, a provider of a clinical intelligence platform for life sciences that powers the next generation of diagnosis and treatments, raised $14 million in a Series A funding round led by Healthier Capital, with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures.
With Series A funding, Dandelion will expand its pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. Dandelion serves clients across the full drug development lifecycle, from discovery through commercialization.
Elliott Green, CEO and Co-Founder of Dandelion Health, said: “This round lets us go deeper with our pharma partners and demonstrate what’s possible when the full richness of a patient’s clinical record is actually brought to bear on drug development.”
“Dandelion is doing something genuinely different in health data — combining the scale of a large real-world dataset with the depth of raw biological signals that most platforms simply cannot access,” said Aman Mahajan, MD, PhD, Partner, Healthier Capital. “The team’s scientific depth and the partners they’ve drawn in make clear why pharma is turning to Dandelion to make smarter decisions across the drug development lifecycle.”
Digital health companies, including AI-powered clinical intelligence software startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Aidoc, a global leader in enterprise-scale clinical AI focused on helping physicians make earlier, safer diagnoses by turning raw patient signals into actionable insight, raised $150 million in a Series E funding round.
In another deal, Iterative Health, an AI-powered healthcare technology and services company powering the acceleration of clinical research, raised $77 million in a Series C financing round.